Endometrial hyperplasia associated with use of tamoxifen in patients with breast cancer in Barranquilla

Authors

  • María Hemer-Cera Universidad del Norte.
  • Ricardo Donado-Botero Universidad del Norte
  • Carmen Barcasnegras-Deavila Universidad del Norte
  • Andres García-Osorio Universidad del Norte
  • Daniel Turcios-Ordoñez Universidad del Norte
  • Ángel Hernández-Lastra Organización Clínica Bonnadona Prevenir
  • Martha Peñuela-Epalzac Universidad del Norte
  • Victor Alfonso Florez Garcia Universidad del Norte https://orcid.org/0000-0002-1548-623X

DOI:

https://doi.org/10.21615/cesmedicina.35.1.2

Keywords:

Tamoxifen, Breast cancer, Complications, Endometrial hyperplasia

Abstract

Introduction: tamoxifen has been the first line drug for the treatment of breast cancer; however, serious adverse events have been evidenced with its use. The aim of this study was to determine endometrial hyperplasia associated with the use of tamoxifen in women with breast cancer in an oncological institution in the city of Barranquilla, Colombia.

Methodology: retrospective case-control study. A total of 202 patients with breast cancer treated between 2012 and 2017 were included. Anthropometric, sociodemographic, personal, clinical and pathological variables were evaluated. Crude and adjusted Odds ratios (OR) were estimated.

Results: 68 participants were diagnosed with endometrial hyperplasia secondary to antineoplastic treatment. Of these, 59 (86.7 %) used tamoxifen, the most of them (37.2 %) for a period of 6-11 months. Bivariate analysis showed an association between endometrial hyperplasia and tamoxifen use with an OR of 3.9 (95%CI: 1.8-8.5) and 2.9 (95%CI: 1.18-7.5) in the crude and adjusted analyses, respectively.

Conclusion: tamoxifen use is associated with the presence of endometrial hyperplasia.

Downloads

Download data is not yet available.

References

International Agency for Research on Cancer (IARC). Global cancer statistics 2018 -GLOBOCAN 2018-. Graph production: IARC (http://gco.iarc.fr/today) World Health Organization. Lyon, France. 2018.

Terán Dávila J, Teppa Garrán AD. Moduladores selectivos de los receptores estrogénicos (SERMs): Bioquímica, farmacología y aplicación clínica en ginecología. Ginecol Obstet Mex. 2005;73(8):424–35.

Yang G, Nowsheen S, Aziz K, Georgakilas AG. Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs. Pharmacol Ther. 2013;139(3):392–404. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23711794

Chicaíza L, Gamboa, O García, M. Tamoxifen vs. Inhibidores de aromatasa para cáncer de mama: análisis de costo efectividad para Colombia. Repositorio Institucional Universidad Nacional. 2008;(2):1-11.

Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep. 1985;(69):237-8.

Lumachi F, Brunello a, Maruzzo M, Basso U, Basso SMM. Treatment of estrogen receptor-positive breast cancer. Curr Med Chem. 2013;20(5):596–604.

Barnard ME, Boeke CE, Tamimi RM. Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochim Biophys Acta. 2015;1856(1):73–85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26071880

Yeung NCY, Zhang Y, Ji L, Lu G, Lu Q. Correlates of sexual quality of life among husbands of Chinese breast cancer survivors. Eur J Oncol Nurs. 2019;(40):63–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31229208

Person H, Guillemin F, Conroy T, Velten M, Rotonda C. Factors of the evolution of fatigue dimensions in patients with breast cancer during the 2 years after surgery. Int J cancer. 2019; (0):0-00; Available from: http://www.ncbi.nlm.nih.gov/pubmed/31228259

Lam WWT, Soong I, Yau TK, Wong KY, Tsang J, Yeo W, et al. The evolution of psychological distress trajectories in women diagnosed with advanced breast cancer: a longitudinal study. Psychooncology. 2013;22(12):2831–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24038545

Chalas E, Costantino JP, Wickerham DL, Wolmark N, Lewis GC, Bergman C, et al. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Am J Obstet Gynecol. 2005;(192):1230–9.

Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2016;27(1):1-25.

Lauby-Secretan B, Dossus L, Marant-Micallef C, His M. Obesity and Cancer. Bull Cancer. 2019;106(7-8):635-646; Available from: http://www.ncbi.nlm.nih.gov/pubmed/31227175

Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol [Internet]. 2010 Dec;11(12):1135–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21087898

Dalbert D, Rodríguez M, Figueredo A, Mural J, Bartt O, Subiela R et al. Tamoxifeno y afecciones endometriales en pacientes con cáncer de mama. Medicina (Buenos Aires). 2013;73(2):97-103.

Swerdlow AJ, Jones ME. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst. 2005;97(5):375–84.

Semiglazov VF, Maksimov SI, Bulgatova EA, Meshkova IE, Chepik OF, Berstein LM. Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen. Vopr Onkol. 2003;49(2):198–204. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12785205

Yin L, Li J, Wei Y, Ma D, Sun Y, Sun Y. Primary ovarian small cell carcinoma of pulmonary type with coexisting endometrial carcinoma in a breast cancer patient receiving tamoxifen: A case report and literature review. Medicine (Baltimore). 2018;97(23):e10900. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29879027

Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2016;27(1):e8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26463434

Jeon J, Kim SE, Lee D-Y, Choi D. Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: a retrospective analysis of 821 biopsies. Breast Cancer Res Treat. 2020;179(1):125–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31541382

Winters S, Martin C, Murphy D, Shokar NK. Breast Cancer Epidemiology, Prevention, and Screening. Prog Mol Biol Transl Sci. 2017;(151):1–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29096890

Piñeros M, Sánchez R, Perry P, García O, Ocampo R, Cendales R. Demoras en el diagnóstico y tratamiento de mujeres con cáncer de mama en Bogotá, Colombia. Salud Publica Mex. 2011;53(6):478–85.

Sánchez G, Gustavo C, Estupiñan C. Factores asociados con el tratamiento oportuno de mujeres con cáncer de mama apoyadas por una organización no gubernamental en Bogotá. Biomédica. 2015;(35):505–12.

Ministerio de Salud y Protección Social. Guía de Práctica Clínica (GPC) para la detección temprana, tratamiento integral, seguimiento y rehabilitación de pacientes con cáncer de mama. Sistema de Seguridad Social, Colombia, 2013. Guía No. 19.

Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, et al. Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. Clin Cancer Res. 2019;25(8):2450–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30573691

Gao JJ, Swain SM. Luminal A Breast Cancer and Molecular Assays: A Review. Oncologist [Internet]. 2018;23(5):556–65. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29472313

Stöger H. Are the new breast cancer subtypes (luminal A, B etc.) of practical impact? Yes. Dtsch Med Wochenschr. 2013;138(41):20-96. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24085364

Celia Thaxter's Garden, Appledore, Isles of Shoals

Downloads

Published

2021-05-04

How to Cite

Hemer-Cera, M., Donado-Botero, R., Barcasnegras-Deavila, C., García-Osorio, A., Turcios-Ordoñez, D., Hernández-Lastra, Ángel, … Florez Garcia, V. A. (2021). Endometrial hyperplasia associated with use of tamoxifen in patients with breast cancer in Barranquilla. CES Medicina, 35(1), 16–25. https://doi.org/10.21615/cesmedicina.35.1.2

Issue

Vol. 35 No. 1 (2021): CES Medicina

Section

Artículo original de investigación científica o tecnológica

License

Copyright (c) 2021 CES Medicina

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Derechos de reproducción (copyright)

Cada manuscrito se acompañará de una declaración en la que se especifique que los materiales son inéditos, que no han sido publicados anteriormente en formato impreso o electrónico y que no se presentarán a ningún otro medio antes de conocer la decisión de la revista. En todo caso, cualquier publicación anterior, sea en forma impresa o electrónica, deberá darse a conocer a la redacción por escrito.

Plagios, duplicaciones totales o parciales, traduccones del original a otro idioma son de responsabilidad exclusiva de los autores el envío.

Los autores adjuntarán una declaración firmada indicando que, si el manuscrito se acepta para su publicación, los derechos de reproducción son propiedad exclusiva de la Revista CES Medicina.

Se solicita a los autores que proporcionen la  información completa acerca de cualquier beca o subvención recibida de una entidad comercial u otro grupo con intereses privados, u otro organismo, para costear parcial o totalmente el trabajo en que se basa el artículo.

Los autores tienen la responsabilidad de obtener los permisos necesarios para reproducir cualquier material protegido por derechos de reproducción. El manuscrito se acompañará de la carta original que otorgue ese permiso y en ella debe especificarse con exactitud el número del cuadro o figura o el texto exacto que se citará y cómo se usará, así como la referencia bibliográfica completa.

Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views

Altmetric

Some similar items: